公开(公告)号：US20160030565A1

公开(公告)日：2016-02-04

申请号：US14873566

申请日：2015-10-02

Applicant: Photocure ASA

Inventor： Hans Christian Wulf ,  Aslak Godal ,  Jo Klaveness ,  Per Harald Fuglerud

IPC: A61K41/00 ,  A61N5/06 ,  A61K31/221

CPC classification number: A61K41/0061 ,  A61K31/221 ,  A61N5/0616 ,  A61N5/062 ,  A61N2005/0652 ,  A61N2005/0662 ,  A61N2005/0663

Abstract: The invention provides the use of a photosensitiser which is a derivative (e.g. an ester) of 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight. Preferably, side effects of PDT are prevented or reduced by using (ii) or (iv) in combination with (i) and/or (ii).

公开(公告)号：US20150150972A1

公开(公告)日：2015-06-04

申请号：US14616278

申请日：2015-02-06

Applicant: Photocure ASA

Inventor： Hans Christian Wulf ,  Aslak Godal ,  Jo Klaveness ,  Per Harald Fuglerud

IPC: A61K41/00 ,  A61N5/06

CPC classification number: A61K41/0061 ,  A61K31/221 ,  A61N5/0616 ,  A61N5/062 ,  A61N2005/0652 ,  A61N2005/0662 ,  A61N2005/0663

Abstract: The invention provides the use of a photosensitiser which is a derivative (e.g. an ester) of 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises:(a) administering to said animal a composition comprising said photosensitiser; and(b) photoactivating said photosensitiser,and side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight. Preferably, side effects of PDT are prevented or reduced by using (ii) or (iv) in combination with (i) and/or (ii).

Abstract translation: 本发明提供了在制备用于光动力学治疗方法（PDT）的组合物中使用作为5-氨基乙酰丙酸（5-ALA）的衍生物（例如酯）或其药学上可接受的盐的光敏剂的用途 ），其中所述PDT包括：（a）向所述动物施用包含所述光敏剂的组合物; 和（b）光活化所述光敏剂，并且通过使用（i） - （iv）中的一种或多种来防止或减少所述PDT的副作用（例如疼痛和/或红斑）：（i）所述组合物包含所述光敏剂 浓度小于10％wt（例如0.5-8％wt），（ii）所述组合物在所述光活化前施用少于2小时（例如30分钟至90分钟），（iii）所述光活化被携带 用光通量小于50mW / cm 2（例如5至40mW / cm 2）的光源，（iv）所述光活化在阳光下进行。 优选地，通过使用（ii）或（iv）与（i）和/或（ii）组合来防止或减少PDT的副作用。

公开(公告)号：US10543272B2

公开(公告)日：2020-01-28

申请号：US14873566

申请日：2015-10-02

Applicant: Photocure ASA

Inventor： Hans Christian Wulf ,  Aslak Godal ,  Jo Klaveness ,  Per Harald Fuglerud

IPC: A61K41/00 ,  A61N5/06 ,  A61K31/221

Abstract: The invention provides the use of a photosensitiser which is a derivative (e.g. an ester) of 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight. Preferably, side effects of PDT are prevented or reduced by using (ii) or (iv) in combination with (i) and/or (ii).